Carsten Boess
Independent DirectorMr. Carsten Boess, M.B.A. is Independent Director of Atrium Therapeutics, Inc. since February 2026. Mr. Boess had been Independent Director at Avidity Biosciences Inc. since April 7, 2020 until February 27, 2026. He is Independent Director at Health Sciences Acquisitions Corporation 2 since August 2020. Mr Boess has experience in senior roles in pharmaceutical and biotech organisations. Mr. Boess served as an Independent Director at Achilles Therapeutics plc since April 1, 2020 until March 20, 2025. Mr. Boess served as an Executive Vice President of Corporate Affairs at Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since August 2015 until February 2020 and previously served as its Chief Business Officer. Mr. Boess served as Chief Financial officer and Senior Vice President of Synageva BioPharma Corp. since May 2011 until 2015. He served as Vice President of International Operations at Insulet Corporation since March 5, 2009 until 2011. He served as Chief Financial Officer of Insulet Corporation from June 8, 2006 to March 5, 2009 and served as its Principal Accounting Officer until March 5, 2009. He served as Chief Financial Officer and Vice President of Alexion Pharmaceuticals, Inc. from February 11, 2004 to March 28, 2005. He served as an Executive Vice President of Finance for Serono Inc. from 2005 to 2006. He also held several financial executive roles at Novozymes of North America and Novo Nordisk in France, Switzerland and China. He was a Member of the Geneva based World Wide Executive Finance Management Team while involved with Serono. He served as Vice President of Finance and Chairman of International Operations Finance Board of Novo Nordisk. He began his career at Novo Nordisk in 1991 as Corporate Controller. Subsequently he took on assignments with increasing responsibility including as Manager, Investor Relations and Finance for Novo Nordisk North America as well as Senior Director of Finance and IT of Novozymes' North American operations. He has been an Independent Director at Inotek Pharmaceuticals Corporation since January 12, 2016. He has been Director of Rocket Pharmaceuticals, Inc. since January 2016. Mr. Boess earned bachelor?s and Master's degrees in Economics and Finance, specializing in Accounting and Finance from the University of Odense, Denmark.
Positions
- Company NameRocket Pharmaceuticals, Inc.Stock CodeRCKTPositionIndependent DirectorColleagues
- GDGaurav D. ShahCEO & Director
- PMPeter M. FongIndependent Chairman of the Board
- MLMartin Louis WilsonGen. Counsel, Secretary, Interim Prin. Financial Officer, Chief Comp. Officer & Chief Corp. Officer
- CSChristopher StevensChief Operating Officer
- JMJoseph ManhedePrincipal Accounting Officer
- JSJonathan SchwartzChief Science & Gene Therapy Officer
- DPDavid P. SouthwellIndependent Director
- RTRoderick Tze Ian WongDirector
- Company NameAtrium Therapeutics, Inc.Stock CodeRNAPositionIndependent DirectorColleagues
- KPKathleen P. GallagherPresident, CEO & Director
- SBSarah BoyceIndependent Chair of the Board of Director
- BWBrendan WinslowChief Financial Officer
- HYHusam YounisChief Scientific Officer
- SKStephanie KenneyChief Corporate Affairs Officer
- SGSteven George HughesChief Medical Officer
- CBCarsten BoessIndependent Director
- TETroy Edward WilsonIndependent Director
- WMW. Michael F. FlanaganIndependent Director
